Generated Narrative with Details

id: 25

meta:

contained: , , , , , , , , , , , , , , , , ,

identifier: 5234342

status: final

code: Microbial susceptibility tests Set (Details : {LOINC code '18769-0' = 'Microbial susceptibility tests Set', given as 'Microbial susceptibility tests Set'})

subject: Patient/5

effective: 08/11/2005 8:44:17 AM

issued: 08/11/2005 10:38:01 AM

performer: Acme Laboratory, Inc

specimen: URINE, CLEAN CATCH/MIDSTREAM

result:

• id: o1; status: final; Microorganism identified in Unspecified specimen by Culture (Details : {LOINC code '11475-1' = 'Microorganism identified in Unspecified specimen by Culture', given as 'Microorganism identified in Unspecified specimen by Culture'}); Patient/5; Acme Laboratory, Inc; KLEBSIELLA PNEUMONIAE (Details )
• id: o2; status: final; Microorganism [#/volume] in Unspecified specimen by Viability count (Details : {LOINC code '43161-9' = 'Microorganism [#/volume] in Unspecified specimen by Viability count', given as 'Microorganism [#/volume] in Unspecified specimen by Viability count'}); Patient/5; Acme Laboratory, Inc; 20000 CFU/ML
• id: o3; status: final; AMPICILLIN/SULBACTAM (Details : {http://example.org/local code 'AMS' = 'AMS', given as 'AMPICILLIN/SULBACTAM'}); Patient/5; Acme Laboratory, Inc; 4 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o4; status: final; AMPICILLIN (Details : {http://example.org/local code 'AM' = 'AM', given as 'AMPICILLIN'}); Patient/5; Acme Laboratory, Inc; 16 U; Resistant (Details : {http://hl7.org/fhir/v2/0078 code 'R' = 'Resistant)
• id: o5; status: final; AZTREONAM (Details : {http://example.org/local code 'ATM' = 'ATM', given as 'AZTREONAM'}); Patient/5; Acme Laboratory, Inc; <=1 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o6; status: final; CEFAZOLIN (Details : {http://example.org/local code 'CFZ' = 'CFZ', given as 'CEFAZOLIN'}); Patient/5; Acme Laboratory, Inc; <=4 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o7; status: final; CEFEPIME (Details : {http://example.org/local code 'FEP' = 'FEP', given as 'CEFEPIME'}); Patient/5; Acme Laboratory, Inc; <=1 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o8; status: final; CEFOTETAN (Details : {http://example.org/local code 'CTN' = 'CTN', given as 'CEFOTETAN'}); Patient/5; Acme Laboratory, Inc; <=4 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o9; status: final; CEFTAZIDIME (Details : {http://example.org/local code 'TAZ' = 'TAZ', given as 'CEFTAZIDIME'}); Patient/5; Acme Laboratory, Inc; <=1 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o10; status: final; CEFTRIAXONE (Details : {http://example.org/local code 'CRO' = 'CRO', given as 'CEFTRIAXONE'}); Patient/5; Acme Laboratory, Inc; <=1 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o11; status: final; CIPROFLOXACIN (Details : {http://example.org/local code 'CIPRO' = 'CIPRO', given as 'CIPROFLOXACIN'}); Patient/5; Acme Laboratory, Inc; <=0.25 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o12; status: final; GENTAMICIN (Details : {http://example.org/local code 'GM' = 'GM', given as 'GENTAMICIN'}); Patient/5; Acme Laboratory, Inc; <=1 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o13; status: final; IMIPENEM (Details : {http://example.org/local code 'IPM' = 'IPM', given as 'IMIPENEM'}); Patient/5; Acme Laboratory, Inc; <=1 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o14; status: final; LEVOFLOXACIN (Details : {http://example.org/local code 'LVX' = 'LVX', given as 'LEVOFLOXACIN'}); Patient/5; Acme Laboratory, Inc; <=0.25 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o15; status: final; NITROFURANTOIN (Details : {http://example.org/local code 'NIT' = 'NIT', given as 'NITROFURANTOIN'}); Patient/5; Acme Laboratory, Inc; 32 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o16; status: final; PIPERACILLIN/TAZOBAC (Details : {http://example.org/local code 'PTZ' = 'PTZ', given as 'PIPERACILLIN/TAZOBAC'}); Patient/5; Acme Laboratory, Inc; <=4 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o17; status: final; TRIMETH/SULFA (Details : {http://example.org/local code 'TRSUV' = 'TRSUV', given as 'TRIMETH/SULFA'}); Patient/5; Acme Laboratory, Inc; <=20 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)
• id: o18; status: final; TOBRAMYCIN (Details : {http://example.org/local code 'TOB' = 'TOB', given as 'TOBRAMYCIN'}); Patient/5; Acme Laboratory, Inc; <=1 U; Susceptible (Details : {http://hl7.org/fhir/v2/0078 code 'S' = 'Susceptible)